S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Cabot Co. (NYSE:CBT) Given Average Recommendation of "Buy" by Analysts

Last updated on Saturday, May 14, 2022 | 2022 MarketBeat

Cabot Co. (NYSE:CBT - Get Rating) has received a consensus recommendation of "Buy" from the nine analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $73.00.

Several equities analysts have recently weighed in on CBT shares. StockNews.com raised Cabot from a "hold" rating to a "buy" rating in a report on Friday. TheStreet raised Cabot from a "c+" rating to a "b" rating in a report on Monday, May 2nd. Zacks Investment Research cut Cabot from a "buy" rating to a "hold" rating and set a $71.00 price target on the stock. in a report on Tuesday, April 5th. Finally, UBS Group increased their price target on Cabot from $71.00 to $85.00 in a report on Wednesday, February 16th.

Shares of CBT opened at $67.76 on Friday. The business's fifty day simple moving average is $68.24 and its two-hundred day simple moving average is $62.89. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.67. Cabot has a 12 month low of $47.59 and a 12 month high of $74.87. The company has a market cap of $3.82 billion, a price-to-earnings ratio of 30.12 and a beta of 1.37.

Cabot (NYSE:CBT - Get Rating) last issued its earnings results on Monday, May 2nd. The specialty chemicals company reported $1.69 EPS for the quarter, beating the consensus estimate of $1.42 by $0.27. Cabot had a return on equity of 29.91% and a net margin of 3.43%. During the same quarter in the prior year, the business posted $1.38 EPS. As a group, research analysts forecast that Cabot will post 6 EPS for the current year.

In related news, SVP Hobart Kalkstein sold 11,805 shares of the firm's stock in a transaction on Wednesday, February 16th. The stock was sold at an average price of $73.50, for a total value of $867,667.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.78% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. increased its stake in Cabot by 0.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 629,678 shares of the specialty chemicals company's stock worth $43,077,000 after buying an additional 4,737 shares in the last quarter. SCW Capital Management LP purchased a new stake in Cabot in the 1st quarter worth $4,124,000. First Trust Advisors LP increased its stake in Cabot by 423.8% in the 1st quarter. First Trust Advisors LP now owns 65,245 shares of the specialty chemicals company's stock worth $4,463,000 after buying an additional 52,788 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in Cabot in the 1st quarter worth $218,000. Finally, Parkside Financial Bank & Trust grew its position in shares of Cabot by 176.0% during the first quarter. Parkside Financial Bank & Trust now owns 414 shares of the specialty chemicals company's stock valued at $28,000 after purchasing an additional 264 shares in the last quarter. Institutional investors and hedge funds own 89.50% of the company's stock.

Cabot Company Profile (Get Rating)

Cabot Corporation operates as a specialty chemicals and performance materials company. It operates through three segments: Reinforcement Materials, Performance Chemicals, and Purification Solutions. The company offers reinforcing carbons used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites.

Featured Articles

Analyst Recommendations for Cabot (NYSE:CBT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Cabot right now?

Before you consider Cabot, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabot wasn't on the list.

While Cabot currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here



Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.